Gail J Roboz - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Gail J Roboz

Showing results (81-90 of 201) with videos related to

Pageof 21

Sort By:

Blood|May 27, 2011

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLJoseph M Scandura, Gail J Roboz, Michelle Moh, et al.

Molecular Cancer Therapeutics|June 18, 2014

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemiaMonica L Guzman, Neng Yang, Krishan K Sharma, et al.

Future Oncology (London, England)|January 20, 2016

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz, Pau Montesinos, Dominik Selleslag, et al.

Haematologica|November 9, 2014

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemiaJeffrey E Lancet, Gail J Roboz, Larry D Cripe, et al.

Transplantation and Cellular Therapy|September 7, 2024

Transplant Outcomes in Myelofibrosis: Impact of Donor Type (Cord Blood Grafts Supported by CD34+ selected Cells [Haplo-Cord] Versus Matched Donors)Nima Ghalehsari, Franco Castillo Tokumori, Zhengming Chen, et al.

Blood|September 10, 2020

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cellsKimihito C Kawabata, Hongliang Zong, Cem Meydan, et al.

Leukemia & Lymphoma|August 25, 2012

Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignanciesMichael J Satlin, David P Calfee, Liang Chen, et al.

Biorxiv : the Preprint Server for Biology|May 13, 2026

eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemiaBiljana Culjkovic-Kraljacic, Leandro Marcelo Martinez, Alyssa Retiz, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaGail J Roboz, Todd Rosenblat, Martha Arellano, et al.

Blood|January 7, 2022

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.

Pageof 21

Search research articles

Showing results (81-90 of 201) with videos related to

Sort By:

Pageof 21

Blood|May 27, 2011

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLJoseph M Scandura, Gail J Roboz, Michelle Moh, et al.

Molecular Cancer Therapeutics|June 18, 2014

Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemiaMonica L Guzman, Neng Yang, Krishan K Sharma, et al.

Future Oncology (London, England)|January 20, 2016

Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemiaGail J Roboz, Pau Montesinos, Dominik Selleslag, et al.

Haematologica|November 9, 2014

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemiaJeffrey E Lancet, Gail J Roboz, Larry D Cripe, et al.

Transplantation and Cellular Therapy|September 7, 2024

Blood|September 10, 2020

BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cellsKimihito C Kawabata, Hongliang Zong, Cem Meydan, et al.

Leukemia & Lymphoma|August 25, 2012

Emergence of carbapenem-resistant Enterobacteriaceae as causes of bloodstream infections in patients with hematologic malignanciesMichael J Satlin, David P Calfee, Liang Chen, et al.

Biorxiv : the Preprint Server for Biology|May 13, 2026

eIF4E and Ezrin cooperate in pseudopods to drive a localized migratory translation program in acute myeloid leukemiaBiljana Culjkovic-Kraljacic, Leandro Marcelo Martinez, Alyssa Retiz, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2014

International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemiaGail J Roboz, Todd Rosenblat, Martha Arellano, et al.

Blood|January 7, 2022

Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.

Pageof 21